Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results